John M. Kirkwood, MD
Professor of Medicine,
Dermatology and Translational Science
Director, Melanoma and Skin Cancer Program


Office Location:
HCC Suite 1.32
5117 Centre Avenue
Pittsburgh, PA 15213-1863
Contact Information:
Office Telephone: 412-623-7707
Lab Telephone: 412-623-3243
Email: kirkwood@pitt.edu


Education

AB; Oberlin, 1969
MD; Yale, 1973

Clinical Experties and Research Interest

Immunotherapy and molecular therapy of melanoma, both in the advanced setting and in the adjuvant setting

Selected Publications

View Dr. Kirkwood's publications on PubMed

  1. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010 Sep 27;207(10):2175-2186. Epub 2010 Sep 6. PubMed PMID: 20819923; PubMed Central PMCID: PMC2947081.
  2. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010 Aug 16;8(1):76. PubMed PMID: 20712892; PMCID: PMC2936304.
  3. Simons DL, Lee G, Kirkwood JM, Lee PP. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical response and outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011 May 5;9(1):52. [Epub ahead of print] PMID: 21545749.PMCID:3114759.
  4. Gogas H, Dani U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. Evaluation of Six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 3;8:108. PMID: 21044351; PMCID: PMC2988721.
  5. Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze M, Kirkwood JM, Kalinski P. Helper activity of NK cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T-cells. J Immunother. 2011 Apr;34(3):270-8. PMCID:3057371.
  6. Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, Watkins SC, Butterfield LH, Kalinski P, Kirkwood JM, Storkus WJ. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther. 2011 Apr; 19(4):805-14. Epub 2010 Dec 28. PMCID3070096.
  7. Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol. 2011 Jan 1;186(1):312-22. Epub 2010 Dec 3. PMID:21131422.
  8. Schaefer C, Butterfield LH, Lee S, Kim G, Visus C, Albers A, Kirkwood JM, Whiteside TL. Function but not phenotype of melanoma peptide-specific CD8+ t cells correlate with survival in a multi-epitope peptide vaccine trial (ECOG 1696). Intl J Cancer. 2011 Oct 24. Doi: 10.1002/ijc.26481. PMID: 22021080.
  9. Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res. 2011 Aug;50(2-3):235-47
  10. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012 Feb 15;72(4):887-96. Epub 2011 Dec 28. PubMed PMID: 22205715; PubMed Central PMCID: PMC3288235
  11. Tarhini AA, Butterfield L, Kalinski P, Shuai Y, Gooding WE, Kirkwood JM. Differing Patterns of Circulating Regulatory T-Cells and Myeloid Derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-alpha or TLR-9 Agonist and GM-CSF with Peptide Vaccination. J Immunother. 2012 Nov;35(9):702-10.PMID:23090079. PMC3513773.